The present invention relates to combination therapies for treating a solid tumour in a subject. The combination therapies comprise (a) an antibody or antigen binding portion thereof that specifically binds to CD40 and (b) a further immunotherapeutic agent with efficacy in the treatment of cancer which agent is not an anti CD40 antibody or antigen binding fragment thereof. The invention also relates to a kits and methods of using such therapies.